drugset
drugset / Trial / NCT07823127

MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)

NCT07823127 ↗

Phase 2 Not yet recruiting 15 enrolled Mirum Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in pregnant women with intrahepatic cholestasis of pregnancy (ICP). This is an open-label study where all participants will receive maralixibat.

Timeline

Start
2027-01-15
Primary completion
2029-01-12
Completion
2029-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Maralixibat Small molecule 10 mg Oral
Subject Maralixibat Small molecule 15 mg Oral

Indications

intrahepatic cholestasis of pregnancy